Philadelphia, United States
Carisma Therapeutics is a clinical stage biopharmaceutical company founded in 2016 and headquartered in Philadelphia, PA. The company focuses on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies for cancer and other serious diseases. Carisma has created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Their slogan, "Pioneering CAR Macrophage Immunotherapy to Target Solid Tumors", encapsulates their innovative approach to treating solid tumors.
In their last Series C investment round on 21 September 2022, Carisma Therapeutics secured $30.00M, drawing investment from a diverse group of backers including HealthCap, Wellington Partners, Agent Capital, MRL Ventures Fund, Solasta Ventures, Symbiosis LLC, TPG Biotech, Pictet Alternative Advisors, Penn Medicine Co-Investment Program, and Livzon Pharmaceutical Group.
The company operates in the Biotechnology, Health Care, Health and Wellness, and Life Sciences industries, positioning itself at the intersection of healthcare and technology to address unmet medical needs with innovative solutions. With its strong investor backing and innovative approach, Carisma Therapeutics is poised to make strides in the field of immunotherapy and cancer treatment.
